Stocks and Investing
Stocks and Investing
Mon, December 7, 2020
[ 12:00 AM ] - WOPRAI
Fri, December 4, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $44 on, Dec 4th, 2020
Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $39 to $44 on, Dec 4th, 2020.
Mani has made no other calls on BBIO in the last 4 months.
There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mani
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $53 on, Monday, October 12th, 2020
Contributing Sources